1-20 of 84
Jeff P. Sharman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the Phase 3 POLARIX trial

Clinical Trials & Observations
Yuqin Song, Herve Tilly, Shinya Rai, Huilai Zhang, Jie Jin, Hideki Goto, Yasuhito Terui, Ho-Jin Shin, Won Seog S Kim, Junning Cao, Jifeng Feng, Hyeon-Seok Eom, Tae Min Kim, Xavier Cheng-Hong Tsai, Jyh-Pyng Gau, Hideo Koh, Liling Zhang, Yongping Song, Yu Yang, Wei Li, He Huang, Kiyoshi Ando, Jeff P. Sharman, Laurie H Sehn, Lilian Bu, Xin Wang, Yanwen Jiang, Jamie Hirata, Calvin Lee, Jun Zhu, Koji Izutsu
Journal: Blood
Blood blood.2022017734.
DOI: https://doi.org/10.1182/blood.2022017734
Published: 2023
Includes: Supplemental data
Journal Articles

Zanubrutinib in Acalabrutinib-Intolerant Patients (Pts) with B-Cell Malignancies

Mazyar Shadman, Ian W. Flinn, Edwin C. Kingsley, Benjamin Freeman, Moshe Yair Levy, Houston Holmes, Charles M. Farber, Arvind Chaudhry, Rocco Crescenzo, Adam Idoine, Xiaoping Zhang, Aileen Cohen, Kunthel By, Jane Huang, Jeff P. Sharman
Journal: Blood
Blood (2022) 140 (Supplement 1): 3655–3657.
DOI: https://doi.org/10.1182/blood-2022-159726
Published: 2022
Journal Articles

Practice Gaps and Barriers in Optimal Care Among Healthcare Professionals Treating Patients with CLL and MCL with BTK Inhibitors: Results of a 2-Phase Qualitative/Quantitative Study

Ryan P. Topping, Alexandra Howson, Timothy A. Quill, Christopher R. Flowers, Jeff P. Sharman
Journal: Blood
Blood (2022) 140 (Supplement 1): 13090–13091.
DOI: https://doi.org/10.1182/blood-2022-169430
Published: 2022
Journal Articles

A CD79b Targeting ADC with Superior Anti-Tumor Activity and Safety Resulting in Significantly Improved Therapeutic Index (TI): Safe and Efficacious CD79b ADC

Bernd Schlereth, Isabella Attinger-toller, Philipp Probst, Romain Bertrand, Ramona Stark, Roger Santimaria, Emma Renard, Rachael Fay, Jeff P. Sharman, Dragan Grabulovski, Philipp Spycher
Journal: Blood
Blood (2022) 140 (Supplement 1): 11568–11569.
DOI: https://doi.org/10.1182/blood-2022-160056
Published: 2022
Journal Articles

Real-World Outcomes with First-Line Ibrutinib (Ibr) Versus Chemoimmunotherapy (CIT) in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Final Analysis Results from the InformCLL Registry

Nilanjan Ghosh, Jeff P. Sharman, Jacqueline C. Barrientos, Danielle Brander, Meghan Gutierrez, Linda Wu, Zaina P. Qureshi, Sandhya Upasani, Maoko Naganuma, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 7047–7049.
DOI: https://doi.org/10.1182/blood-2022-155649
Published: 2022
Journal Articles

Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study

Alex F. Herrera, Ronald McCord, Patrick Kimes, Fabrice Jardin, Georg Lenz, Marek Trneny, Christopher R. Flowers, Laurie H. Sehn, Gilles Salles, Jeff P. Sharman, Hervé Tilly, Jonathan W. Friedberg, Charles Herbaux, Matthew J. Matasar, Corinne Haioun, Samuel Tracy, Jamie Hirata, Calvin Lee, Yanwen Jiang, Franck Morschhauser
Journal: Blood
Blood (2022) 140 (Supplement 1): 1297–1300.
DOI: https://doi.org/10.1182/blood-2022-157559
Published: 2022
Journal Articles

Phase 2 Trial to Evaluate Safety of Subcutaneous Epcoritamab Monotherapy in the Outpatient Setting Among Patients with Relapsed or Refractory Diffuse Grade 1-3a Large B-Cell and Follicular Lymphoma (EPCORE NHL-6)

Jeff P. Sharman, Ralph V. Boccia, Thomas Doerr, Kristin Conte, Yang Bai, Brian Elliott, David J. Andorsky
Journal: Blood
Blood (2022) 140 (Supplement 1): 9491–9492.
DOI: https://doi.org/10.1182/blood-2022-157575
Published: 2022
Journal Articles

Contribution of Obinutuzumab to Acalabrutinib Therapy in Patients with Treatment-Naive Chronic Lymphocytic Leukemia: Analysis of Survival Outcomes By Genomic Features

Matthew S. Davids, Jeff P. Sharman, Toby A. Eyre, Jennifer A. Woyach, Paulo Andre P. de Miranda, Mina Shahkarami, Anna Butturini, Ugochinyere Emeribe, John C. Byrd
Journal: Blood
Blood (2022) 140 (Supplement 1): 4173–4175.
DOI: https://doi.org/10.1182/blood-2022-157018
Published: 2022
Journal Articles

Genomic Characterization of Patients in a Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients with Relapsed/Refractory B-Cell Malignancies

Linlin Xu, Mazyar Shadman, Anusha Ponakala, Ian W. Flinn, Moshe Yair Levy, Ryan Porter, John M. Burke, Syed F. Zafar, Jennifer L. Cultrera, Jamal Misleh, Edwin C. Kingsley, Habte Yimer, Benjamin Freeman, Arvind Chaudhry, Praveen K. Tumula, Mitul Gandhi, Aileen Cohen, Dih-Yih Chen, Sudhir Manda, Jeff P. Sharman, Vanitha Ramakrishnan
Journal: Blood
Blood (2022) 140 (Supplement 1): 9269–9271.
DOI: https://doi.org/10.1182/blood-2022-167758
Published: 2022
Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study

Jonathan W. Friedberg, Carrie A. Thompson, Marek Trněný, Franck Morschhauser, Gilles Salles, Patrick M. Reagan, Mark Hertzberg, Piotr Smolewski, Huilai Zhang, Catherine Thieblemont, Bei Hu, Gustavo Fonseca, Won-Seog Kim, Maurizio Martelli, Amitkumar Mehta, Avrita Campinha-Bacote, Mark Yan, Jamie Hirata, Matthew Sugidono, Calvin Lee, Jeff P. Sharman
Journal: Blood
Blood (2022) 140 (Supplement 1): 6623–6626.
DOI: https://doi.org/10.1182/blood-2022-157761
Published: 2022
Journal Articles

Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Yuliya Linhares, Cesar Freytes, Mohamad Cherry, Carlos Bachier, Michael Maris, Daanish Hoda, Juan Carlos Varela, Courtney Bellomo, Scott Cross, James Essell, Suzanne Fanning, Howard Terebelo, Habte Yimer, Jay Courtright, Jeff P. Sharman, Min Vedal, Connor Mailley, Ricardo Espinola, Bassam Mattar
Journal: Blood
Blood (2022) 140 (Supplement 1): 10416–10418.
DOI: https://doi.org/10.1182/blood-2022-159595
Published: 2022
Journal Articles

The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Hervé Tilly, Franck Morschhauser, Laurie H. Sehn, Jonathan W. Friedberg, Marek Trněný, Jeff P. Sharman, Charles Herbaux, John M. Burke, Matthew Matasar, Shinya Rai, Koji Izutsu, Neha Mehta-Shah, Lucie Oberic, Adrien Chauchet, Wojciech Jurczak, Yuqin Song, Richard Greil, Larysa Mykhalska, Juan Miguel Bergua Burgués, Matthew C. Cheung, Antonio Pinto, Ho-Jin Shin, Greg Hapgood, Eduardo Munhoz, Pau Abrisqueta Costa, Jyh-Pyng Gau, Jamie Hirata, Yanwen Jiang, Mark Yan, Calvin Lee, Christopher R. Flowers, Gilles Salles
Journal: Blood
Blood (2021) 138 (Supplement 2): LBA-1.
DOI: https://doi.org/10.1182/blood-2021-154729
Published: 2021
Journal Articles

Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study

Ryan Jacobs, Wojciech Jurczak, Ian W. Flinn, Sebastian Grosicki, Krzysztof Giannopoulos, Tomasz Wróbel, Syed F. Zafar, Jennifer L. Cultrera, Suman Kambhampati, Alexey V. Danilov, John M. Burke, Jerome Goldschmidt, Douglas F. Beach, Scott F. Huntington, Javier Pinilla Ibarz, Jeff P. Sharman, Tanya Siddiqi, Danielle M. Brander, Mazyar Shadman, John M. Pagel, Monika Dlugosz-Danecka, Nilanjan Ghosh, Kathryn S. Kolibaba, Peter Sportelli, Hari P. Miskin, Owen A. O'Connor, Michael S. Weiss, John G. Gribben
Journal: Blood
Blood (2021) 138 (Supplement 1): 3726.
DOI: https://doi.org/10.1182/blood-2021-147460
Published: 2021
Journal Articles

Debulking before Initiation of Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Results from a Phase 3b Study

Ian W. Flinn, David Andorsky, Jason Melear, Sudhir Manda, Bertrand Anz, III, Kathryn Kolibaba, Habte Yimer, John M. Burke, Suzanne Fanning, Jay Courtright, Miguel Islas-Ohlmayer, Suman Kambhampati, Tamas Vizkelety, John Pesko, Brenda Chyla, Dingfeng Jiang, Jeff P. Sharman
Journal: Blood
Blood (2021) 138 (Supplement 1): 3725.
DOI: https://doi.org/10.1182/blood-2021-147258
Published: 2021
Journal Articles

BRUIN CLL-321: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

Jeff P. Sharman, Wojciech Jurczak, Catherine C. Coombs, Marisa Hill, Denise Wang, Nora C. Ku, Ananya Guntur, Safi Shahda, Ching Ching Leow, Paolo Ghia, Anthony R. Mato
Journal: Blood
Blood (2021) 138 (Supplement 1): 3736.
DOI: https://doi.org/10.1182/blood-2021-145926
Published: 2021
Journal Articles

Favorable Outcomes for Patients Treated with U2 with Co-Morbidities or Concomitant Medications: A Retrospective Analysis of Unity-CLL Phase 3 Trial

Javier Pinilla Ibarz, Wojciech Jurczak, Suman Kambhampati, Ewa Lech Maranda, Tomasz Wróbel, Jeff P. Sharman, Syed F. Zafar, Marc Hoffmann, Scott F. Huntington, Ryan Jacobs, Osnat Bairey, Chris Rowland, Hari P. Miskin, Peter Sportelli, Michael S. Weiss, Owen A. O'Connor, Ian W. Flinn
Journal: Blood
Blood (2021) 138 (Supplement 1): 3748.
DOI: https://doi.org/10.1182/blood-2021-151292
Published: 2021
Journal Articles

Completed Induction Phase Analysis of Magnify: Phase 3b Study of Lenalidomide + Rituximab (R 2 ) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Frederick Lansigan, David Jacob Andorsky, Morton Coleman, Abdulraheem Yacoub, Jason Melear, Suzanne Fanning, Kathryn S. Kolibaba, Christopher M. Reynolds, Grzegorz S. Nowakowski, Mecide Gharibo, Jung Ryun Ahn, Ju Li, Mathias J. Rummel, Jeff P. Sharman
Journal: Blood
Blood (2021) 138 (Supplement 1): 812.
DOI: https://doi.org/10.1182/blood-2021-145640
Published: 2021
Journal Articles

BRUIN MCL-321: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (Trial in Progress)

Toby A. Eyre, Nirav N. Shah, Steven Le Gouill, Martin H. Dreyling, Elisabeth Vandenberghe, Wojciech Jurczak, Yucai Wang, Chan Yoon Cheah, Mitul D. Gandhi, Christopher H. Chay, Jeff P. Sharman, David Jacob Andorsky, Ming Yin, Minna Balbas, Jennifer Kherani, Michael L. Wang
Journal: Blood
Blood (2021) 138 (Supplement 1): 2422.
DOI: https://doi.org/10.1182/blood-2021-145920
Published: 2021
Journal Articles

Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed/Refractory B-Cell Malignancies

Mazyar Shadman, Ian W. Flinn, Moshe Y. Levy, Ryan Porter, John M. Burke, Jennifer L. Cultrera, Jamal Misleh, Syed F. Zafar, Benjamin Freeman, Subramanya S. Rao, Habte Yimer, Arvind Chaudhry, Mitul D. Gandhi, Troy H. Guthrie, Edwin Kingsley, Praveen K. Tumula, Sudhir Manda, Dih-Yih Chen, Aileen Cohen, Kunthel By, Linlin Xu, Ye Liu, Jeff P. Sharman
Journal: Blood
Blood (2021) 138 (Supplement 1): 1410.
DOI: https://doi.org/10.1182/blood-2021-148544
Published: 2021
Journal Articles

Variance in Practice between Experts and Oncology Healthcare Professionals for Follicular Lymphoma: Analysis of an Online Treatment Decision Tool

Rachael M. Andrie, John M. Burke, Ian W. Flinn, John P. Leonard, Jeff P. Sharman, Timothy A. Quill, Kristen Rosenthal, Christopher R. Flowers
Journal: Blood
Blood (2021) 138 (Supplement 1): 1922.
DOI: https://doi.org/10.1182/blood-2021-152937
Published: 2021